| Detailed information |
|---|
| CancerLivER ID | 2570 |
| Biomarker | MAP2K4, MAP2K5, SF1, SIAHBP1, and MYOG |
| Biomarker Name/Symbol (given in Publication) | MAP2K4, MAP2K5, SF1, SIAHBP1, and MYOG |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HVB-HCC; but not validated on independent dataset |
| Experimental Condition | HBV-HCC vs HCV -HCC; associated with the progression of HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in B-type HCC |
| Level of significance | P< 0.05 |
| Source | Tissue |
| PMID | 12124323 |
| Type of Biomarker | Diagnostic |
| Pathway | signal transduction or transcription |
| Cohort | Surgical specimens were obtained from 45 patients who underwent surgical treatment for HCC at Yamaguchi University Hospital between May 1997 and August 2000. Of the 45 patients, 14 were positive for serum HBs Ag and 31 were positive for HCV Ab; none were positive for both HBs Ag and HCV Ab. Thus, th |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HBV-HCC vs HCV -HCC |
| Year of Publication | 2002 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |